{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:04:15Z","timestamp":1790258655792,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Background: Multiple myeloma (MM) is a hematological cancer caused by a proliferation\nof clonal plasma cells, leading to anemia, renal failure, hypercalcemia and destructive bone lesions\nresulting in significant morbidity. The overall survival has significantly improved with the incorporation\nof immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI).<\/jats:p>\n                    <jats:p>Objective: Here we provide a comprehensive review on IMiDs including molecular mechanisms,\nrecent advances in therapeutic applications and management of toxicities in the treatment of MM.<\/jats:p>\n                    <jats:p>Methods: Relevant publications in peer reviewed journals were retrieved by a selective search of\nPubMed. Systemic reviews, meta-analyses, randomized controlled trials, and treatment recommendations\nwere reviewed and are summarized here.<\/jats:p>\n                    <jats:p>Results: Thalidomide, a first generation IMiD, is associated with significant toxicity in older patients.\nLenalidomide, a more potent second generation IMiD with fewer side effects than thalidomide,\nis commonly used in newly-diagnosed multiple myeloma, relapsed refractory myeloma and as\nmaintenance therapy after autologous stem cell transplantation (ASCT). Pomalidomide, a third generation\nIMiD, is 10 times more potent than lenalidomide and has shown impressive results in relapsed\nMM patients and in those refractory to both lenalidomide and bortezomib.<\/jats:p>\n                    <jats:p>Conclusion: The clinical use of IMiDs in MM has significantly improved long-term survival and\nquality of life. Future studies are looking into novel biomarkers predictive of outcome in MM and\nnew combinations of lenalidomide and pomalidomde with PI, monoclonal antibodies, immune\ncheckpoint blockers and several other chemotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1568009617666170214104426","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T17:08:04Z","timestamp":1487869684000},"page":"846-857","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Immunomodulatory Drugs (IMiDs) in Multiple Myeloma"],"prefix":"10.2174","volume":"17","author":[{"given":"Shahzad","family":"Raza","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, College of Physicians and Surgeons, Columbia University, New York, NY,United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A.","family":"Safyan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, College of Physicians and Surgeons, Columbia University, New York, NY,United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, College of Physicians and Surgeons, Columbia University, Herbert Irving Pavilion, R 953, 161 Ft. Washington Ave, New York, NY 10032,United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009617666170214104426","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/150090\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009617666170214104426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:01:03Z","timestamp":1761332463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/150090\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009617666170214104426","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2015-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}